Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment.

Hdl Handle:
http://hdl.handle.net/10147/292283
Title:
Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment.
Authors:
Memon, Adeel R; Butler, Joseph S; O'Riordan, Michael V; Guerin, Elizabeth; Dimitrov, Borislav D; Harty, James A
Affiliation:
Department of Trauma and Orthopaedics, Cork University Hospital, Cork, Ireland. dowite2003@hotmail.com
Citation:
Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment., 16 (1):118-24 J Clin Densitom
Journal:
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
Issue Date:
17-May-2013
URI:
http://hdl.handle.net/10147/292283
DOI:
10.1016/j.jocd.2012.07.003
PubMed ID:
22959779
Abstract:
Complex pathways affect bone metabolism at the cellular level, and a balance between osteoblast and osteoclast activity is critical to bone remodeling. One of the major pathways affecting bone metabolism is Wnt/β-catenin signaling, and its disturbances lead to a wide range of bone abnormalities. An important antagonist of this pathway is Dickkopf-1 (Dkk1). Higher Dkk1 levels have been associated with increased bone loss due to inhibition of Wnt pathway. Currently, bisphosphonates are the most commonly used agents to treat primary osteoporotic patients. This study demonstrates the effect of bisphosphonates on Dkk1 levels and its correlation with bone mineral density (BMD). Eighty patients with low BMD were recruited and divided into 2 groups of 40 each (bisphosphonate treatment group and control group). The mean Dkk1 level in the treatment group was significantly reduced to 2358.18 vs 3749.80 pg/mL in the control group (p<0.001). Pearson correlation coefficient showed negative correlation between Dkk1 and BMD at lumbar spine (r=-0.55) and femoral neck in the control group; however, no such correlation was found in the treatment group (r=-0.05). Hence, bisphosphonate therapy leads to reduction in Dkk1 levels, but it does not correlate with BMD in such patients.
Item Type:
Article
Language:
en
Keywords:
BONE DENSITY
MeSH:
Aged; Bone Diseases, Metabolic; Bone Remodeling; Cross-Sectional Studies; Diphosphonates; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Osteoporosis
ISSN:
1094-6950

Full metadata record

DC FieldValue Language
dc.contributor.authorMemon, Adeel Ren_GB
dc.contributor.authorButler, Joseph Sen_GB
dc.contributor.authorO'Riordan, Michael Ven_GB
dc.contributor.authorGuerin, Elizabethen_GB
dc.contributor.authorDimitrov, Borislav Den_GB
dc.contributor.authorHarty, James Aen_GB
dc.date.accessioned2013-05-17T15:14:38Z-
dc.date.available2013-05-17T15:14:38Z-
dc.date.issued2013-05-17-
dc.identifier.citationComparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment., 16 (1):118-24 J Clin Densitomen_GB
dc.identifier.issn1094-6950-
dc.identifier.pmid22959779-
dc.identifier.doi10.1016/j.jocd.2012.07.003-
dc.identifier.urihttp://hdl.handle.net/10147/292283-
dc.description.abstractComplex pathways affect bone metabolism at the cellular level, and a balance between osteoblast and osteoclast activity is critical to bone remodeling. One of the major pathways affecting bone metabolism is Wnt/β-catenin signaling, and its disturbances lead to a wide range of bone abnormalities. An important antagonist of this pathway is Dickkopf-1 (Dkk1). Higher Dkk1 levels have been associated with increased bone loss due to inhibition of Wnt pathway. Currently, bisphosphonates are the most commonly used agents to treat primary osteoporotic patients. This study demonstrates the effect of bisphosphonates on Dkk1 levels and its correlation with bone mineral density (BMD). Eighty patients with low BMD were recruited and divided into 2 groups of 40 each (bisphosphonate treatment group and control group). The mean Dkk1 level in the treatment group was significantly reduced to 2358.18 vs 3749.80 pg/mL in the control group (p<0.001). Pearson correlation coefficient showed negative correlation between Dkk1 and BMD at lumbar spine (r=-0.55) and femoral neck in the control group; however, no such correlation was found in the treatment group (r=-0.05). Hence, bisphosphonate therapy leads to reduction in Dkk1 levels, but it does not correlate with BMD in such patients.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometryen_GB
dc.subjectBONE DENSITY-
dc.subject.meshAged-
dc.subject.meshBone Diseases, Metabolic-
dc.subject.meshBone Remodeling-
dc.subject.meshCross-Sectional Studies-
dc.subject.meshDiphosphonates-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIntercellular Signaling Peptides and Proteins-
dc.subject.meshMale-
dc.subject.meshOsteoporosis-
dc.titleComparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Trauma and Orthopaedics, Cork University Hospital, Cork, Ireland. dowite2003@hotmail.comen_GB
dc.identifier.journalJournal of clinical densitometry : the official journal of the International Society for Clinical Densitometryen_GB
dc.description.provinceMunsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.